Literature DB >> 18372147

Contemporary outcomes after superficial femoral artery angioplasty and stenting: the influence of TASC classification and runoff score.

Daniel M Ihnat1, Son T Duong, Zachary C Taylor, Luis R Leon, Joseph L Mills, Kaoru R Goshima, Jose A Echeverri, Bulent Arslan.   

Abstract

OBJECTIVE: A recent randomized trial suggested nitinol self-expanding stents (SES) were associated with reduced restenosis rates compared with simple percutaneous transluminal angioplasty (PTA). We evaluated our results with superficial femoral artery (SFA) SES to determine whether TransAtlantic InterSociety Consensus (TASC) classification, indication for intervention, patient risk factors, or Society of Vascular Surgery (SVS) runoff score correlated with patency and clinical outcome, and to evaluate if bare nitinol stents or expanded polytetrafluoroethylene (ePTFE) covered stent placement adversely impacts the tibial artery runoff.
METHODS: A total of 109 consecutive SFA stenting procedures (95 patients) at two university-affiliated hospitals from 2003 to 2006 were identified. Medical records, angiographic, and noninvasive studies were reviewed in detail. Patient demographics and risk factors were recorded. Procedural angiograms were classified according to TASC Criteria (I-2000 and II-2007 versions) and SVS runoff scores were determined in every patient; primary, primary-assisted, secondary patency, and limb salvage rates were calculated. Cox proportional hazard model was used to determine if indication, TASC classification, runoff score, and comorbidities affected outcome.
RESULTS: Seventy-one patients (65%) underwent SES for claudication and 38 patients (35%) for critical limb ischemia (CLI). Average treatment length was 15.7 cm, average runoff score was 4.6. Overall 36-month primary, primary-assisted, and secondary rates were 52%, 64%, and 59%, respectively. Limb salvage was 75% in CLI patients. No limbs were lost following interventions in claudicants (mean follow-up 16 months). In 24 patients with stent occlusion, 15 underwent endovascular revision, only five (33%) ultimately remained patent (15.8 months after reintervention). In contrast, all nine reinterventions for in-stent stenosis remained patent (17.8 months). Of 24 patients who underwent 37 endovascular revisions for either occlusion or stenosis, eight (35%) had worsening of their runoff score (4.1 to 6.4). By Cox proportional hazards analysis, hypertension (hazard ratio [HR] 0.35), TASC D lesions (HR 5.5), and runoff score > 5 (HR 2.6) significantly affected primary patency.
CONCLUSIONS: Self-expanding stents produce acceptable outcomes for treatment of SFA disease. Poorer patency rates are associated with TASC D lesions and poor initial runoff score; HTN was associated with improved patency rates. Stent occlusion and in-stent stenosis were not entirely benign; one-third of patients had deterioration of their tibial artery runoff. Future studies of SFA interventions need to stratify TASC classification and runoff score. Further evaluation of the long-term effects of SFA stenting on tibial runoff is needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18372147     DOI: 10.1016/j.jvs.2007.12.050

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  15 in total

Review 1.  An overview of optimal endovascular strategy in treating the femoropopliteal artery: mechanical, biological, and procedural factors.

Authors:  Nicolas W Shammas
Journal:  Int J Angiol       Date:  2013-03

Review 2.  Contemporary treatment for critical ischemia: the evidence for interventional radiology or surgery.

Authors:  Keith Hussey; Sivanathan Chandramohan
Journal:  Semin Intervent Radiol       Date:  2014-12       Impact factor: 1.513

3.  Long-term results of open and endovascular revascularization of superficial femoral artery occlusive disease.

Authors:  Salvatore T Scali; Eva M Rzucidlo; Aja A Bjerke; David H Stone; Daniel B Walsh; Philip P Goodney; Catherine K Chang; Richard J Powell
Journal:  J Vasc Surg       Date:  2011-05-28       Impact factor: 4.268

4.  Ten years after arterial bypass surgery for claudication: venous bypass is the primary procedure for TASC C and D lesions.

Authors:  Thomas Eugster; Regula Marti; Lorenz Gurke; Peter Stierli
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

5.  Clinical outcomes after endovascular treatment of superficial femoral disease in patients with disabling claudication and critical limb ischemia: midterm analysis.

Authors:  A J Misselt; M D Zielinski; O I Garcia Medina; G Oderich; H Bjarnason; M A McKusick; Sanjay Misra
Journal:  Angiology       Date:  2011-08-25       Impact factor: 3.619

Review 6.  Sex Differences in Peripheral Artery Disease.

Authors:  Maria Pabon; Susan Cheng; S Elissa Altin; Sanjum S Sethi; Michael D Nelson; Kerrie L Moreau; Naomi Hamburg; Connie N Hess
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

7.  Proceedings from the Society of Interventional Radiology research consensus panel on critical limb ischemia.

Authors:  Sanjay Misra; Robert Lookstein; John Rundback; Alan T Hirsch; William R Hiatt; Michael R Jaff; Christopher R White; Michael Conte; Patrick Geraghty; Manesh Patel; Kenneth Rosenfield
Journal:  J Vasc Interv Radiol       Date:  2013-04       Impact factor: 3.464

8.  Detailed cross-sectional study of 60 superficial femoral artery occlusions: morphological quantitative analysis can lead to a new classification.

Authors:  Mickaël Ohana; Soraya El Ghannudi; Elie Girsowicz; Anne Lejay; Yannick Georg; Fabien Thaveau; Nabil Chakfe; Catherine Roy
Journal:  Cardiovasc Diagn Ther       Date:  2014-04

9.  Comparisons between prosthetic vascular graft and saphenous vein graft in femoro-popliteal bypass.

Authors:  Keun-Myoung Park; Young Wook Kim; Shin-Seok Yang; Dong-Ik Kim
Journal:  Ann Surg Treat Res       Date:  2014-06-24       Impact factor: 1.859

10.  Gender-specific risk factors for peripheral artery disease in a voluntary screening population.

Authors:  Jade S Hiramoto; Ronit Katz; Steven Weisman; Michael Conte
Journal:  J Am Heart Assoc       Date:  2014-03-13       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.